Abstract. We examined the role of osteopontin (OPN) in NIKand MEKK1-dependent MMP-9 activation, melanoma growth and lung metastasis and its clinical significance in malignant melanoma. Here we report that OPN induces αvß3 integrinmediated MEKK1-dependent JNK1 phosphorylation. OPN stimulates NIK-or JNK1-dependent c-Jun expression. In contrast, OPN induces MEKK1-dependent JNK1 activation that leads to downregulation of ERK1/2 activation. OPN triggers NIK-and MEKK1-dependent AP-1 activation whereas NIK-dependent AP-1 activation is independent of JNK1 that leads to pro-MMP-9 activation. In vivo studies indicate that the levels of pNIK and MMP-9 are significantly higher in the OPN-induced primary tumor and metastasized lung compared to control. Clinical data revealed that the enhanced level of OPN and pNIK expression in the skin biopsies correlates with Clark's level and Breslow thickness. Altogether, OPN regulates negative cross-talk between NIK/ERK and MEKK1/ JNK1 pathways that controls melanoma progression.
Introduction
Osteopontin (OPN), is an RGD-containing non-collagenous, sialic acid-rich phosphoglycoprotein. It is a member of the extracellular matrix (ECM) protein family (1, 2) . It has an Nterminal signal sequence and a highly acidic region consisting of nine consecutive aspartic acid residues (3) . It binds with several integrins and CD44 variants in an RGD sequencedependent and -independent manner (4). This protein is involved in normal tissue remodeling processes such as bone resorption, angiogenesis, wound healing, and tissue injury as well as certain diseases such as tumorigenesis, restenosis, atherosclerosis and autoimmune diseases (5) . OPN expression is upregulated in several cancers and is reported to associate with tumor progression and metastasis (6, 7) . It has been reported that OPN induces MT1-MMP-mediated pro-matrix metalloproteinase-2 (pro-MMP-2) activation and urokinase type plasminogen activator (uPA)-mediated pro-matrix metalloproteinase-9 (pro-MMP-9) activation, cell motility, ECM invasion and tumor growth (8) (9) (10) .
MEKK1, a member of the MAP3K family is a mammalian serine/threonine protein kinase. It was initially identified on the basis of its homology with STE11 and activates the pheromone responsive MAPK cascade in yeast (11) . Previous data indicated that overexpression of constitutively active forms of MEKK1 leads to JNK activation via phosphorylation of its upstream kinase, MKK4 (12) . Nuclear factor inducing kinase (NIK) is another member of the MAP3K family that has been implicated in NFκB activation. Few reports indicate that NIK may also be involved in the regulation of transcription factor, AP-1 (13) . Various MAPK cascades (e.g. ERK1/2, JNK, p38) are often portrayed as linear cascades and indications of crosstalk between the various cascades are limited (14) . However, the cross-talk between NIK/ERK and MEKK1/JNK pathways in response to OPN that ultimately regulates melanoma growth and lung metastasis has not been well documented.
MMPs are extracellular matrix (ECM) degrading enzymes that play a critical role in embryogenesis, tissue remodeling, inflammation and angiogenesis (15) . MMP-9, also referred to as type IV collagenase or gelatinase B, efficiently degrades native type IV and V collagens, fibronectin, ectactin and elastin and hence plays a major role in invasion, tumor growth and metastasis (16) . MMP-9 has also been implicated in angiogenesis, rheumatoid arthritis, retinopathy and vascular stenosis and is considered to be a prioritized therapeutic target (17) .
In this study, we have demonstrated that OPN induces αvß3 integrin mediated NIK-and/or MEKK1-dependent cJun expression leading to AP-1 transactivation and MMP-9 activation in B16F10 cells. This OPN-induced MEKK1 and NIK-mediated AP-1 transactivation occurs through both JNKdependent and -independent pathways. OPN also induces a negative cross-talk between NIK/ERK and MEKK1/JNK1 pathways leading to MMP-9 activation that ultimately controls melanoma growth and lung metastasis. The levels of pNIK and MMP-9 are significantly higher in the OPN-induced metastasized lung compared to control. Clinical data revealed the enhanced level of OPN and pNIK expression in the skin biopsies that correlates with Clark's level and Breslow thickness that in turn reflects the melanoma grades.
In vivo tumorigenicity experiments. The tumorigenicity experiments were performed as described previously (8, 10) . The cells were either treated with purified human OPN (10 μM) or transfected with wild-type and kinase-negative NIK or wild-type and kinase-negative MEKK1 in the presence of Lipofectamine Plus and then treated with OPN and injected subcutaneously into the flanks of male athymic NMRI (nu/nu) mice. Six mice were used in each set of experiments. OPN (10 μM) was again injected into the tumor sites twice a week for up to 4 weeks. After 4 weeks, the mice were sacrificed and the tumor weights were measured.
In vivo lung metastasis study. Cells were treated with OPN or stably transfected with wild-type and kinase-negative NIK and then treated with OPN, and then injected into the lateral tail veins of nude mice. The mice were sacrificed after eight weeks and the lungs were removed, washed with water and fixed. Sections of the lungs were stained with H&E to confirm that the nodules were melanoma specific. The levels of expression of pNIK and MMP-9 were detected by immunostaining with their specific antibodies followed by FITC and analyzed by confocal microscopy (Zeiss).
Clinical specimens for immunohistochemical studies. Human primary melanoma tissue samples were collected with informed consent, from either diagnostic biopsies or upon surgery from a local hospital. Based on the clinical investigations, they were classified as malignant melanomas (MMs) with metastasis and MMs without metastasis. Clinical and histopathological data are summarized in Table I . Immunohistochemical studies were performed on the primary cutaneous lesions.
Plasmids and DNA transfection. The luciferase reporter construct (pAP-1-Luc) containing seven tandem repeats of the AP-1 binding site was from Stratagene. Cells were transiently transfected with cDNA using Lipofectamine Plus according to the manufacturer's instructions as described previously (9) .
Immunoprecipitation and Western blot analysis. The levels of pMEKK1, MEKK1, pJNK1, JNK1, ERK, c-Jun and actin from treated or transfected B16F10 cell lysates or nuclear extracts were analyzed either by immunoprecipitation followed by Western blotting or direct Western blotting using their specific antibodies (8, 9) .
In vitro kinase assay. The JNK1 or ERK kinase assays using c-Jun or myelin basic protein (MBP) as substrate were performed as described (9, 10) .
AP-1 luciferase reporter gene assay. The AP-1 luciferase assays were performed by transfecting the cells with luciferase reporter construct (pAP-1-Luc) or cotransfecting with wildtype and kinase-negative NIK or wild-type and kinase-negative MEKK1 followed by treatment with OPN. The transfection efficiency was normalized by cotransfecting the cells with pRL vector. The luciferase activity was measured by a luminometer and changes in luciferase activity with respect to control were calculated.
Zymography. The gelatinolytic activity of MMP-9 in treated or transfected cells was measured as described (10) .
Results

OPN induced αvß3 integrin-dependent MEKK1 and JNK1 phosphorylation.
To study the effect of OPN on MEKK1 phosphorylation, B16F10 cells were treated with 5 μM OPN at 37˚C. Cell lysates were immunoprecipitated with anti-MEKK1 antibody and immunoblotted with anti-phosphoserine antibody. The data revealed that OPN induces MEKK1 phosphorylation (Fig. 1A) . In separate experiments, cells were either pretreated with anti-αvß3 integrin antibody or transfected with mut NIK or wt and mut MEKK1 and then treated with OPN and used for JNK1 phosphorylation. αvß3 integrin antibody or mut MEKK1 but not mut NIK suppressed the OPN-induced JNK1 phosphorylation in these cells (Fig. 1B) . All the bands were quantified by densitometric analysis and the fold-changes were calculated. These results demonstrated that OPN induces MEKK1 and JNK1 phosphorylation through an αvß3 integrinmediated but NIK-independent pathway.
OPN-induced JNK kinase activity was regulated by MEKK1
but not by NIK. To examine the role of NIK and MEKK1 in regulating OPN-induced JNK1 activity, cells were transfected with wild-type and kinase-negative NIK or wild-type and kinase-negative MEKK1 and then treated with OPN. JNK1 kinase assay was performed. The data revealed that wild-type MEKK1 enhanced whereas mut MEKK1 suppressed the OPNinduced JNK activity (Fig. 1C) . The data also indicated that OPN-induced JNK1 activity was unaffected upon transfection Table I . Analysis of OPN and pNIK expression and its correlation with metastatic potential in various grades of malignant melanoma specimens.
Left second finger
MM, malignant melanoma; NM, nodular melanoma; and SSM, superficial spreading melanoma. n=3 in each case.
-
of cells with both wild-type and mut NIK (Fig. 1D) . The same blots were reprobed with anti-JNK1 antibody as loading control. These data suggested that MEKK1 but not NIK regulates OPN-induced JNK1 activity.
Overexpression of active MEKK-1 attenuated OPN-induced ERK1/2 activation. MEKK-1 functions as a MAPKKK in the JNK pathway; however several reports have suggested that MEKK-1 may also affect the ERK pathway (14) . Previous results indicated that JNK -/-mice showed enhanced ERK phosphorylation leading to tumor growth (18), therefore we speculated that activation of JNK1 by OPN may play a role in suppression of ERK1/2 activation. Accordingly, cells were transfected with wild-type and mut MEKK1 or wild-type JNK1 and then treated with OPN. In a separate experiment, cells were pretreated with SP600125 and then treated with OPN. ERK kinase activity was performed using MBP as a substrate. The data indicated that overexpression of wild-type MEKK1 and wild-type JNK1 completely attenuated OPNinduced ERK activation. Treatment with SP600125 partially suppressed the OPN-induced ERK activity ( Fig. 2A) . Half of the immunoprecipitated samples were immunoblotted with anti-ERK1/2 antibody. These results suggested that MEKK1 negatively regulates OPN-induced ERK activation.
OPN induced MEKK1-and NIK-mediated c-Jun expression.
To determine the effect of OPN on c-Jun expression and to examine the role of MEKK1 and NIK in this process, cells were either treated with OPN or transfected with wt and mutant forms of NIK and MEKK1 and then treated with OPN. The level of c-Jun expression was detected by Western blotting using anti-c-Jun antibody. The results indicated that OPN induced c-Jun expression (Fig. 2B) . Wild-type NIK and MEKK1 enhanced whereas mut NIK and MEKK1 suppressed OPN-induced c-Jun expression. Actin was used as loading control. These data indicated that OPN induced c-Jun expression through both NIK-and MEKK1-dependent pathways.
OPN induced NIK-and MEKK1-dependent AP-1 transactivation.
To further investigate the role of NIK and MEKK1 in OPN-induced AP-1 transactivation, luciferase reporter gene assay was performed. Cells were either transfected with AP-1 luciferase reporter construct (pAP-1-Luc) or cotransfected with wild-type and mut NIK or wild-type and mut MEKK1 along with pAP-1-Luc and then treated with OPN. Cotransfecting the cells with pRL vector normalized the transfection efficiency. Changes in luciferase activity with respect to control were determined. The fold-changes are represented as a bar graph. The results are expressed as the means + S.E. of three determination. The values were also analyzed by Student's t-test (p<0.002). The data showed that wild-type NIK and MEKK1 enhanced but mut NIK and MEKK1 suppressed OPN-induced AP-1 activity in these cells (Fig. 2C) . These data indicated that OPN induced AP-1 transactivation through NIK and MEKKmediated pathways.
OPN stimulated MEKK1-mediated MMP-9 activation. The effect of MEKK1 on OPN-induced MMP-9 activation was determined by zymography. Cells were transfected with wild-type and mut MEKK1 and then treated with OPN. The conditioned media were collected and used for gelatinolytic activity by zymography. An increased level of MMP-9 activation (86 kDa) was observed when cells were treated with OPN antibody and JNK1 kinase assay was performed using recombinant c-Jun as substrate (upper panels). The remaining half of the immunoprecipitated samples was immunoblotted with anti-JNK1 antibody (lower panels) as controls. All these bands were analyzed densitometrically and the fold-changes were calculated. The data shown here represent three experiments exhibiting similar effects. (Fig. 2D) . Almost no MMP-9 specific band was detected in the untreated cells. Wild-type MEKK1 enhanced whereas mut MEKK1 suppressed OPN-induced MMP-9 activation.
OPN induced NIK/MEKK1-dependent melanoma growth in nude mice.
The in vitro data prompted us to examine whether NIK and MEKK1 play any role in OPN-induced tumor growth in nude mice. Accordingly, cells were either treated with OPN or transfected with wild-type and mut NIK or wild-type and mut MEKK1 followed by treatment with OPN and then injected subcutaneously into the flanks of nude mice. The mice were sacrificed after four weeks and the tumor weights were measured. The fold-change was determined and is represented in the form of a bar graph (Fig. 3A) . There was a 6-and 5.4-fold increase in tumor weight when wt NIK-or wt MEKK1-transfected cells were injected respectively. The tumor size was significantly less in mice injected with mut NIK-or mut MEKK1-transfected cells. The changes in tumor weights were also analyzed statistically by Student's t-test (p<0.002).
Role of NIK on melanoma metastasis to lungs.
To examine the role of NIK in regulating OPN-induced MMP-9 expression in lung metastasis of melanoma, cells were stably transfected with wild-type and mut NIK and then treated with OPN and injected through the lateral tail vein into nude mice. The mice were sacrificed after 8 weeks and the lungs were removed and fixed in Bouin's solution for 24 h to facilitate counting of tumor nodules using a dissecting microscope. Fig. 3B shows that wild-type NIK increased the formation of metastatic nodules (lung colonies) compared to mutant NIK or OPN injected lungs. The levels of MMP-9 ( Fig. 3B) and pNIK (Fig. 3C) were analyzed in lung sections by immunohistochemistry. The data indicated that the level of pNIK was significantly higher in OPN-treated metastasized lung compared to control and MMP-9 expression was significantly higher in wild-type NIK-transfected samples treated with OPN compared to OPN alone or mutant NIK-transfected cells treated with OPN. These data clearly demonstrated for the first time that pNIK and MMP-9 play a crucial role in OPN-regulated melanoma metastasis to lungs.
Expression of OPN and pNIK in human MM specimens.
In order to correlate the in vitro data and in vivo mouse model results to human clinical specimens, primary melanoma tissues were collected with informed consent, from either diagnostic biopsies or upon surgery. The levels of expression of OPN and pNIK were determined by immunohistochemical analysis. The results revealed that OPN and pNIK were present in human malignant melanoma specimens of all 12 patients with four different cases (3 MM with metastasis and 1 MM without metastasis). Moreover, there was significant positive correlation between the expression of OPN and pNIK and melanoma progression in human specimens of all four cases (Fig. 4) . Clinical and histopathological data are summarized in Table I . Immunohistochemical studies were performed on the primary cutaneous lesions and Clark's level and Breslow thickness were determined. The levels of OPN and pNIK expression were determined by immunofluorescence staining using the respective primary antibodies followed by either FITC-or HRP-conjugated IgG and analyzed using confocal microscopy. Note that there was a significant positive correlation between OPN and pNIK expression and metastatic potential in different grades of melanoma specimens. These clinical and histopathological data are summarized in Table I .
Discussion
Recent studies have demonstrated that downregulation of NIK activation does not affect TNFα-induced JNK activation (19) . It has been also reported that ERK and JNK pathways play a crucial role in regulating MMP-9 activation and cell motility in growth factor stimulated human epidermal keratinocytes (20) . These results prompted us to investigate whether binding of OPN to αvß3 integrin receptor regulates JNK1 activation and whether NIK is involved in this activation process. We have shown that OPN induces αvß3 integrinmediated MEKK1 and JNK1 phosphorylation whereas JNK1 phosphorylation is MEKK1-dependent but NIK-independent. Shen et al have recently reported that sustained activation of JNK blocks ERK activation in response to EGF and PMA (21) . Our data demonstrated a negative cross-talk between OPN-induced NIK/ERK and MEKK1/JNK1 activation and further suggested that sustained activation of JNK resulted in the attenuation of ERK activation. Previous studies have indicated that MEKK1 has the ability to activate ERK but the effect is less potent (22) . This may be implicated to the short and long phase of MEKK1 activation, which results in different cellular responses, a short-phase activation which leads to ERK activation and long-phase activation resulting in inhibition of ERK activation. Also the inhibition of OPN-induced NIKmediated ERK activation caused by overexpression of wildtype MEKK1 involves the ability of MEKK1 to activate the JNK pathway. These implications delineate a mechanism in which treatment with the same agonist may result in a different cellular outcome depending on the duration of treatment. This data is consistent with the recent report that JNK1 deficiency stimulates TPA-induced ERK phosphorylation leading to enhanced skin tumorigenesis (18) . Natoli et al have reported that overexpression of NIK, which does not activate JNK, strongly activates transcription directed by a canonical AP-1 site (19) . Because we have shown that OPN induces MEKK1-dependent but NIK-independent JNK phosphorylation and the AP-1 response element is present in the promoter region of the MMP-9 gene, we sought to determine the level of c-Jun expression upon OPN stimulation. Our data indicated that OPN induces both NIK-and MEKK1-mediated c-Jun expression leading to AP-1 transactivation. Overexpression of NIK did not affect JNK activation but significantly upregulated AP-1 transcriptional activity indicating that OPN induces NIKdependent AP-1 activation, which is independent of JNK. In summary, we have reported that OPN induces pro-MMP-9 activation through NIK/ERK and MEKK1/JNK-mediated AP-1 dependent pathways. The in vitro data is also supported by in vivo findings, which showed that OPN enhances both NIK-and MEKK1-mediated tumor growth and lung metastasis in nude mice. The levels of pNIK and MMP-9 are significantly higher in the primary tumor and metastasized lung compared to control. Clinical data revealed the enhanced level of OPN and pNIK expression in the skin biopsies, which correlated with Clark's level and Breslow thickness that in turn, reflected the melanoma grade. These results highlight the potential role of OPN and the molecular mechanism underlying the genesis of metastasis signature in melanoma and hence may be useful in developing novel molecular diagnostics and targeted therapy for the treatment of malignant melanoma.
